Amgen, Garmin Among Relative Market Leaders Poised to Outperform in Coming Months: BTIG
Investors in Amgen (NASDAQ:AMGN) Have Seen Splendid Returns of 122% Over the Past Five Years
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Beat the Market Like Zacks: Karooooo, UnitedHealth, Amgen in Focus
The trend of weight loss drug sector in US stock market is diverging. Novo Nordisk (NVO.US) and Eli Lilly and Co (LLY.US) face challenges to their duopoly.
As more and more pharmaceutical companies enter the lucrative weight loss drug market to get a share of the pie, the increasing competition is making investors worried about the duopoly position of Novo Nordisk and Eli Lilly and Co in this market.
Here Are Big Pharma's Leading Blockbuster Makers
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
Express News | Amgen Says Currently Assessing Global IT Outage Impact And Working To Recover Impacted Systems As Quickly As Possible
Express News | Amgen Inc - Are Currently Assessing Global It Outage Impact and Are Working to Recover Impacted Systems as Quickly as Possible.
Jefferies Adjusts Price Target on Amgen to $380 From $375
Jefferies Maintains Amgen(AMGN.US) With Buy Rating, Raises Target Price to $380
Express News | Amgen Inc : BMO Raises Target Price to $362 From $355
Rivals Emerge to Ozempic and Zepbound -- but With a Lag -- Heard on the Street -- WSJ
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Amgen's Mixed Financial Outlook: Balancing Revenue Prospects With Operational Concerns and Product Pipeline Uncertainty
PairX Bio Clinches Coveted Amgen Golden Ticket Award, as NSG BioLabs Deepens Efforts With Partners CapitaLand and Amgen to Boost Singapore's Biotech Ecosystem With Fourth Site and Extended Awards Programme
Unpacking the Latest Options Trading Trends in Amgen
A Closer Look at Amgen's Options Market Dynamics